We believe personnalized medicine and targeted therapies are amazing therapeutic alternatives for many patients.
Our work focus on bringing chemical innovation to antibody-drug conjugates, a sub-class of targeted therapies, in order to ensure optimal characteristics and efficacies.
To date, McSAF have developped McSAF Inside® cysteins rebridging technology platforms that can be used to produce three typologies of ADCs:
- DAR 4, i.e. 4 drugs per antibody
- DAR 2, i.e. 2 drugs per antibody
- DAR 1, i.e. 1 drug per antibody
McSAF Inside®, a versatile technology
McSAF Inside® results
DAR 4
Results obtained on ADC with MMAE conventional linker (native mass spectrometry analysis)
DAR 2
Results obtained on ADC with MMAE click linker (native mass spectrometry analysis)
DAR 1
Results obtained on ADC with MMAE click linker (mass spectrometry analysis)
BIBLIOGRAPHY
> Novel antibody-drug conjugates and the use of same in therapy Joubert, N ; Viaud-Massuard, MC ; Respaud, R. Patent WO2015004400A1.
Patent delivered in FR / US / JP / EP
> Antibody-drug conjugates and their use in therapy Juen, L ; Baltus, CB Patent WO2020234541.
> Anti-CD30-drug conjugates and their use in therapy Juen, L ; Baltus, CB Patent WO2021064332.
> Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody-Drug Conjugates Feuillâtre O. et al., ACS Omega, 2020, 5, 1557-1565
>Innovative Bioconjugation Technology for Antibody–Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model Juen L. et al., Bioconjugate Chemistry, 2021, 32, 3, 595-606